Service Delivery and Safety Department World Health Organization, Headquarters

Size: px
Start display at page:

Download "Service Delivery and Safety Department World Health Organization, Headquarters"

Transcription

1 Service Delivery and Safety Department World Health Organization, Headquarters WHO global (laboratory-based) survey on multidrug-resistant organisms (MDROs) in health care PROJECT SUMMARY Given the important profile of antimicrobial resistance (AMR) within WHO, as highlighted in a recent Executive Board Resolution (EB134.R13), this survey aims to collect data on the prevalence of multidrug-resistant organisms (MDROs) from laboratories in a wide range of health-care facilities. The outcome will be a data summary and interpretation document, including information on the capacity of health-care laboratory testing. This survey is unique and is in support of the annual WHO SAVE LIVES: Clean Your Hands global campaign, with the related document being issued on the campaign celebration day of 5 May RATIONALE AND BACKGROUND INFORMATION AMR is of global concern 1. This is mainly due to the emergence, substantial rise and spread of antibiotic resistant bacteria in health-care facilities. Infections caused by drug-resistant pathogens increase mortality across all settings, and can lead to prolonged stays in hospital and increased risk of admission to intensive care units. This situation is particularly worrying since no new class of antibacterial agents has been developed in the past 25 years, thus limiting therapeutic options to treat these bacterial infections. Over the last few years, WHO regional offices and HQ have committed to take urgent action to assess the burden of AMR worldwide, lead efforts to combat AMR spread and report to Member States. Several resolutions were developed and adopted at the Regional level and a Resolution was very recently adopted by the 134 th Executive Board (EB134.R13). Every year on 5 May, since 2009, the WHO SAVE LIVES: Clean Your Hands campaign has launched a call to action to implement and sustain hand hygiene improvement worldwide, to reduce microbial transmission of health-care associated infections (HAI).The focus of the 2014 call is the role of hand hygiene in reducing the spread of AMR. Among the activities to support this call, WHO is proposing a global survey to assess and raise awareness of the burden of the five key MDROs that have been identified at the global level, as causing most colonization and infection in patients in health-care facilities. The resulting data will be unique, in that it will not only provide information on the global burden of these pathogens, but will also assess the robustness of laboratory-testing methods. For more information on WHO SAVE LIVES: Clean Your Hands and the 5 May 2014 call to action focusing on hand hygiene and AMR, visit WHO is urging health-facilities to take part in this year s call to action, including the surveys proposed, to progress understanding of global AMR; information that will support everyone in their efforts to better manage patient infections and care, as well as costs. STUDY GOAL AND OBJECTIVES The main goal is to present information from a global survey on the burden of MDROs in a wide range of health-care facilities, in support of WHO s 5 May 2014 activities focused on AMR. Data will be requested from health-care facilities laboratories in all WHO regions through the WHO SAVE LIVES: Clean Your Hands campaign communications plan, as well as by gathering the support of the WHO CleanHandsNet network and other infection control networks. It is expected that participating facilities will be registered with the WHO campaign if not already

2 Currently, the SAVE LIVES: Clean Your Hands campaign has over health-care facilities signed up to it, across 168 countries. The main objectives are to: 1) conduct a global survey on the burden of MDROs from clinical blood and urinary specimens routinely submitted to participating laboratories for inpatients in a wide range of health-care facilities; 2) understand the techniques used in health-care laboratories for the identification and susceptibility testing of inpatient blood and urine specimens. Data will be related to blood culture and urine (Mid-Stream Urine [MSU] and Catheter Specimen Urine [CSU] samples to assess the prevalence of five selected key MDROs: 1. Methicillin-resistant Staphylococcus aureus [MRSA]* 2. Vancomycin-resistant enterococci [VRE ]** 3. Extended-spectrum β-lactamase [ESBL] producing Enterobacteriaceae 4. Carbapenem Resistant Enterobacteriaceae [CRE], and 5. Multi-resistant Acinetobacter spp [MRAB] *MRSA Staphyloccous aureus which are resistant to methicillin/oxacillin/cefoxitin. **VRE Enterococci spp. which are resistant to glycopeptide antibiotics (i.e. vancomycin or teicoplanin). ESBL Gram-negative organisms that mediate resistance to extended-spectrum third generation cephalosporins, (e.g. ceftazidime, cefotaxime, and ceftriaxone) and monobactams (e.g. aztreonam) but do not affect cephamycins (e.g. cefoxitin and cefotetan) or carbapenems (e.g. meropenem or imipenem). 2 CRE Enterobacteriaceae that produce any β-lactamase that hydrolyses carbapenems (any or all of ertapenem, doripenem, imipenem and meropenem) and are resistant to all of the following third-generation cephalosporins: ceftriaxone, cefotaxime, and ceftazidime. 3,4 MRAB Multi-resistant Acinetobacter spp.: Isolate resistant to at least three classes of antimicrobial agents, i.e. all penicillins and cephalosporins (including inhibitor combinations), fluoroquinolones, and aminoglycosides. 5 STUDY DESIGN This is a global survey with online submission of data based on a WHO closed-question questionnaire to be completed by laboratories in health-care facilities managing inpatient blood and urine samples. Inclusion criteria: health-care settings registered for the WHO SAVE LIVES: Clean Your Hands global campaign and other WHO-associated networks, accepting to participate in the survey upon invitation. Expected duration: data collection will take place over one week between 1 March - 13 June METHODS This project is being run in collaboration with the WHO Collaborating Centre on Patient Safety at the University of Geneva Hospitals, directed by Professor Didier Pittet.

3 Participants will be recruited through the global call from WHO HQ, primarily through campaign communications to the SAVE LIVES: Clean Your Hands and WHO CHN databases and stakeholders. The survey, undertaken by eligible participants, will be based on the routine, ordinary collection of clinical blood and urine (MSU & CSU) culture specimens. Invited laboratories will be asked to report the first isolate from inpatients, only during the study week proposed by WHO HQ. Surveys should be conducted in laboratories serving inpatient health-care facilities for one continuous week (7 days) from 1 March - 13 June Data should be collected by the laboratory staff during any one week identified within this time frame, and returned to WHO in a single electronic form by 15 June The name of the laboratory staff member completing the survey will be required to answer any queries, but will not be used for any other purpose. All data, including staff identity will be kept strictly confidential by WHO. Secured online data submission has been developed to support the survey and the online data collection is based on the survey questionnaire outlined in Annex 1; no modifications will be made. Confidentiality clauses are to be signed by all bodies supporting data collection, with data review only accessible to internal WHO staff with all measures available put in place to ensure data protection. Data collection, analysis, reporting and project management will be conducted by WHO in collaboration with the WHO Collaborating Centre at the University Hospitals of Geneva. WHO commits to keeping the individual facility names and data strictly confidential. Overall pooled data, with no facility identification information, will be disseminated by WHO. An example of a similar anonymous data summary document disseminated by WHO is the Summary Report of the 2011 WHO Hand Hygiene Self-Assessment Framework Global Survey, available at The survey will be available in English, French and Spanish CONFIDENTIALITY This survey will be conducted through a secure online data submission system using Datacol at WHO. The system generates a personalized link connected to the of the person invited by WHO to participate. Health-care facilities registered for WHO SAVE LIVES: Clean Your Hands and other WHO-associated networks will be invited to participate by a personalized invitation explaining the aim of the survey, providing instructions and a unique link automatically generated by the platform. The invitation will be sent from the WHO SAVE LIVES: Clean Your Hands address (savelives@who.int). In all cases, WHO commits to keeping the individual facility names and results strictly confidential. SAFETY CONSIDERATIONS Any serious concerns that arise from the laboratories reports will be addressed through the WHO report including recommendations on how antimicrobial resistance reporting can be improved. FOLLOW-UP The WHO Clean Care is Safer Care team in collaboration with the WHO Collaborating Centre on Patient Safety will follow up the survey for its duration, by answering enquiries sent by participants to the WHO address dedicated to the WHO SAVE LIVES: Clean Your Hands campaign (savelives@who.int), and sharing and collaborating with any survey coordinators. Furthermore, after data collection, if appropriate, the WHO Clean Care is Safer Care team will

4 discuss results to identify best strategies for recommendations to health-care facilities in the perspective of further laboratory testing improvements. DATA MANAGEMENT AND STATISTICAL ANALYSIS Data will be analyzed by the WHO Collaborating Centre on Patient Safety, in collaboration with the WHO Clean Care is Safer Care team. Detailed and summary descriptive analysis by country and region will be performed. Results will not be given by facility in order to avoid any identification. As for previous similar WHO ERC-approved surveys, results will be summarized by country only when at least ten health care facilities have submitted their results (see Summary Report of the 2011 WHO Hand Hygiene Self-Assessment Framework Global Survey at EXPECTED OUTCOMES OF THE STUDY A summary results report will be issued on the WHO web site featuring anonymised, collated data by WHO region and country, if possible. Based on the results, important information will be highlighted with regards to MDROs occurring in a wide range of acute health-care facilities, as well as laboratory methods/capabilities. ETHICS Given that neither patients nor health-care workers are involved, there are no main ethics considerations arising from this project. Regarding data management, health-care facilities are assured that confidentiality will be maintained regarding their identity. No informed consent is, therefore, required for this survey. QUALITY ASSURANCE Since data will be collected only through the forms submitted by laboratory personnel across the world, variations in laboratory methods used to identfy MDROs are expected, based on the resources and facilities available. For this reason, the questions regarding laboratory methods included in the survey will allow WHO to have an insight into the level of data quality, although quality assurance during the survey is not seen as the overall aim. PROJECT MANAGEMENT Prof. Benedetta Allegranzi, principal investigator, Service Delivery and Safety, World Health Organization, HQ, Geneva, Switzerland. Prof. Didier Pittet, co-investigator, data analysis, WHO Collaborating Centre on Patient Safety, University of Geneva Hospitals, Geneva, Switzerland. Dr Nizam Damani, co-investigator, survey designer and lead data reporter, Service Delivery and Safety, World Health Organization, HQ, Geneva, Switzerland. Ms Claire Kilpatrick and Dr Zeynep Kubilay, co-investigators, survey promotion and communications and recruitment activities, Service Delivery and Safety, World Health Organization, HQ, Geneva, Switzerland. REFERENCES 1. WHO: The evolving threat of antimicrobial resistance:options for action. Geneva: World Health Organization, CDC Laboratory detection of Extended -spectrum β lactamsases (ESBL). Access on 15tth January CDC Tool kit. Guidance for Control of Carbapenem-resistantEnterobacteriaceae. Atlanta: CC, UK Health Protection Agency. Laboratory detection and reporting of bacteria with carbapenem-hydrolysing β-lactamases (carbapenemases). London: Health Protection Agency, Multidrug-resistant, extensively drug-resistant and pan drug-resistant bacteria: an international expert proposal for interim standard. definitions for acquired resistance. Clin Microbiol Infect 2012; 18:

5 Annex 1 WHO global (laboratory-based) survey on multidrug-resistant organisms (MDROs) in health care DATA COLLECTION FORM Duration of survey: Any one continuous week between 1 March - 13 June 2014 Name of the acute health-care facility Name of the laboratory City Postcode Country Laboratory staff member completing the survey Surname (Capital letter) First name (Capital letter) Type of acute health-care facility Public Private Not-for-profit General Teaching Other.. Total number of acute care inpatient beds in the facility: Is the facility registered for WHO SAVE LIVES: Clean Your Hands ( Is a Clinical Microbiologist employed in the laboratory service?

6 CLINICAL LABORATORY ISOLATES FROM BLOOD AND URINE CULTURES OVER A ONE WEEK PERIOD Instructions for completion Complete this form with data related to ONE CONTINUOUS WEEK between 1 March -13 June 2014 Include only first isolate from inpatients during the study week. For urine, use both Midstream and Catheter Specimens (MSU, CSU). Dates of survey period: from... to.... Total no. of blood cultures set (aerobic & anaerobic) processed per year (approx.) Total no. of blood cultures set (aerobic & anaerobic) processed during the week of the survey.. Total no. of inpatient urine specimens processed per year (approx.)..... Total no. of inpatient urine specimens processed during the week of the survey. Positive blood cultures (survey week) Positive urine cultures (survey week) Total no. of all Gram positive microorganisms identified Total no. of Staphylococcus aureus No. of MRSA Total no. of Enterococci spp No. of VRE Total no. of all Gram negative microorganisms identified Total no. of Enterobacteriaceae spp Total no.of E.coli No.of ESBL E.coli No.of CRE E.coli Total no.of Klebsiella spp No.of ESBL Klebsiella spp

7 No.of CRE Klebsiella spp. No.of ESBL other in Enterobacteriaceae spp. (excluding E.coli and Klebsiella spp) No.of CRE in other Enterobacteriaceae spp (excluding E.coli and Klebsiella spp) Total no. of Acinetobacter spp No.of multidrug resistant Acinetobacter spp Total no. of fungi (including yeast) Total no. of other non-bacterial, non fungal species LABORATORY IDENTIFICATION OF MDROs Identification of Staphylococcus aureus Gram stain Slide or Tube coagulase Non-automated method If yes, state the method (API etc.) :.... Automated method If yes, state the method (Vitek, Phoenix, MALDI-TOF etc): Other identification methods: (molecular & non-molecular):. Identification of Enterococcus spp Gram stain Streptococcal Lancefeild grouping Non-automated method

8 If yes, state the method (API etc.) :.. Automated method If yes, state the method (Vitek, Phoenix, MALDI-TOF etc): Other identification methods: (molecular & non-molecular):. Identification of Enterobacteriaceae spp Gram stain Chromogenic Agar If yes, manufacturer s name... Non-automated method If yes, state the method (API etc.) :.. Automated method If yes, state the method (Vitek, Phoenix, MALDI-TOF etc): Other identification methods: (molecular & non-molecular):.. LABORATORY CONFIRMATION OF RESISTANCE Which antibiotic interpretative criteria is used for disc diffusion, break point and MIC (Minimum Inhibitory Concentration) in your laboratory? CLSI EUCAST BSAC Other :..

9 MRSA (Methicillin-resistant Staphycoccus aureus) Disc diffusion method If Yes, which antibiotic disc is used? Methicillin 10μg Oxacillin 1μg Cefoxitin 10μg Cefoxitin 30μg E test MIC (Broth method or agar dilution) Non-automated susceptibility testing method If yes, state the method.. Automated susceptibility testing method If yes, state the method (Vitek, Phoenix etc.)... Other methods: (molecular & non-molecular):. VRE (Vancomycin-resistant enterococci) Disc diffusion method If Yes, which antibiotic disc is used: Vancomycin 5 μg Vancomycin 30 μg Teicoplanin 30 μg

10 E test MIC (Broth method or agar dilution) Non-automated susceptibility testing method If yes, state the method.. Automated susceptibility testing method If yes, state the method (Vitek, Phoenix etc.)... Other methods: (molecular & non-molecular):. ESBL (Extended-Spectrum Beta-Lactamase) Presence of an ESBL is confirmed by : Chromogenic ESBL agar If yes, manufacturer s name... ESBL combi-discs If yes, manufacturer s name... Disc approximation ESBL E-tests MIC (Broth method or agar dilution) for 3 rd generation cephalosporins Non-automated susceptibility testing method If yes, state the method.. Automated susceptibility testing method

11 If yes, state the method (Vitek, Phoenix etc.)... Other methods: (molecular & non-molecular):. CRE (Carbapenem Resistant Enterobacteriaceae) Presence of CPE is confirmed by: Chromogenic CPE agar If YES, product and manufacturer s name.. Modified Hodge Test MIC (Broth method or agar dilution) for Carbapenems Non-automated susceptibility testing method If yes, state the method.. Automated susceptibility testing method If yes, state the method (Vitek, Phoenix etc.)... Other methods: (molecular & non-molecular):. LABORATORY QUALITY CONTROL Agar plates used in the laboratory are : Purchased pre-poured media Prepared in the laboratory If prepared in the laboratory, do you quality control your media?

12 Quality control organisms used or susceptability in your laboratory testing MRSA NO ATCC NCTC other If other, please specify... VRE NO ATCC NCTC other If other, please specify. CRE NO ATCC NCTC other If other, please specify... ESBL NO ATCC NCTC other If other, please specify... Does your laboratory participate in the External Quality Control Scheme? YES NO Does your country have a Reference Laboratory to confirm CRE and other multidrug-resistant organisms? Don't know Additional comments WHO thanks you very much for your contribution to this important global survey in support of the SAVE LIVES: Clean Your Hands 5 May 2014 call to action.

WHO laboratory-based global survey on multidrug-resistant organisms (MDROs) in health care interim analysis

WHO laboratory-based global survey on multidrug-resistant organisms (MDROs) in health care interim analysis WHO laboratory-based global survey on multidrug-resistant organisms (MDROs) in health care interim analysis Aim: to estimate the burden of MDROs isolated among inpatients in a wide range of health-care

More information

Safe Patient Care Keeping our Residents Safe Use Standard Precautions for ALL Residents at ALL times

Safe Patient Care Keeping our Residents Safe Use Standard Precautions for ALL Residents at ALL times Safe Patient Care Keeping our Residents Safe 2016 Use Standard Precautions for ALL Residents at ALL times #safepatientcare Do bugs need drugs? Dr Deirdre O Brien Consultant Microbiologist Mercy University

More information

New Opportunities for Microbiology Labs to Add Value to Antimicrobial Stewardship Programs

New Opportunities for Microbiology Labs to Add Value to Antimicrobial Stewardship Programs New Opportunities for Microbiology Labs to Add Value to Antimicrobial Stewardship Programs Patrick R. Murray, PhD Senior Director, WW Scientific Affairs 2017 BD. BD, the BD Logo and all other trademarks

More information

ESBL Producers An Increasing Problem: An Overview Of An Underrated Threat

ESBL Producers An Increasing Problem: An Overview Of An Underrated Threat ESBL Producers An Increasing Problem: An Overview Of An Underrated Threat Hicham Ezzat Professor of Microbiology and Immunology Cairo University Introduction 1 Since the 1980s there have been dramatic

More information

Antibiotic Resistance in the Post-Acute and Long-Term Care Settings: Strategies for Stewardship

Antibiotic Resistance in the Post-Acute and Long-Term Care Settings: Strategies for Stewardship Antibiotic Resistance in the Post-Acute and Long-Term Care Settings: Strategies for Stewardship J. Hudson Garrett Jr., PhD, MSN, MPH, FNP-BC, PLNC, CDONA, IP-BC, GDCN, CDP, CADDCT, CALN, VA-BC, AS-BC,

More information

03/09/2014. Infection Prevention and Control A Foundation Course. Talk outline

03/09/2014. Infection Prevention and Control A Foundation Course. Talk outline Infection Prevention and Control A Foundation Course 2014 What is healthcare-associated infection (HCAI), antimicrobial resistance (AMR) and multi-drug resistant organisms (MDROs)? Why we should be worried?

More information

Florida Health Care Association District 2 January 13, 2015 A.C. Burke, MA, CIC

Florida Health Care Association District 2 January 13, 2015 A.C. Burke, MA, CIC Florida Health Care Association District 2 January 13, 2015 A.C. Burke, MA, CIC 11/20/2014 1 To describe carbapenem-resistant Enterobacteriaceae. To identify laboratory detection standards for carbapenem-resistant

More information

EXTENDED-SPECTRUM BETA-LACTAMASE (ESBL) TESTING

EXTENDED-SPECTRUM BETA-LACTAMASE (ESBL) TESTING EXTENDED-SPECTRUM BETA-LACTAMASE (ESBL) TESTING CHN61: EXTENDED-SPECTRUM BETA-LACTAMASE (ESBL) TESTING 1.1 Introduction A common mechanism of bacterial resistance to beta-lactam antibiotics is the production

More information

Two (II) Upon signature

Two (II) Upon signature Page 1/5 SCREENING FOR ANTIBIOTIC RESISTANT ORGANISMS (AROS) IN ACUTE CARE AND LONG TERM CARE Infection Prevention and Control IPC 050 Issuing Authority (sign & date) Office of Administrative Responsibility

More information

a. 379 laboratories provided quantitative results, e.g (DD method) to 35.4% (MIC method) of all participants; see Table 2.

a. 379 laboratories provided quantitative results, e.g (DD method) to 35.4% (MIC method) of all participants; see Table 2. AND QUANTITATIVE PRECISION (SAMPLE UR-01, 2017) Background and Plan of Analysis Sample UR-01 (2017) was sent to API participants as a simulated urine culture for recognition of a significant pathogen colony

More information

Summary of the latest data on antibiotic resistance in the European Union

Summary of the latest data on antibiotic resistance in the European Union Summary of the latest data on antibiotic resistance in the European Union EARS-Net surveillance data November 2017 For most bacteria reported to the European Antimicrobial Resistance Surveillance Network

More information

EARS Net Report, Quarter

EARS Net Report, Quarter EARS Net Report, Quarter 4 213 March 214 Key Points for 213* Escherichia coli: The proportion of patients with invasive infections caused by E. coli producing extended spectrum β lactamases (ESBLs) increased

More information

European Committee on Antimicrobial Susceptibility Testing

European Committee on Antimicrobial Susceptibility Testing European Committee on Antimicrobial Susceptibility Testing Routine and extended internal quality control for MIC determination and disk diffusion as recommended by EUCAST Version 8.0, valid from 018-01-01

More information

Protocol for Surveillance of Antimicrobial Resistance in Urinary Isolates in Scotland

Protocol for Surveillance of Antimicrobial Resistance in Urinary Isolates in Scotland Protocol for Surveillance of Antimicrobial Resistance in Urinary Isolates in Scotland Version 1.0 23 December 2011 General enquiries and contact details This is the first version (1.0) of the Protocol

More information

Hand Hygiene and MDRO (Multidrug-resistant Organisms) - Science and Myth PROF MARGARET IP DEPT OF MICROBIOLOGY

Hand Hygiene and MDRO (Multidrug-resistant Organisms) - Science and Myth PROF MARGARET IP DEPT OF MICROBIOLOGY Hand Hygiene and MDRO (Multidrug-resistant Organisms) - Science and Myth PROF MARGARET IP DEPT OF MICROBIOLOGY MDROs and Hand Hygiene Guidelines HH Apr14 The Science of Hand Hygiene in Healthcare Settings

More information

Infection Prevention Highlights for the Medical Staff. Pamela Rohrbach MSN, RN, CIC Director of Infection Prevention

Infection Prevention Highlights for the Medical Staff. Pamela Rohrbach MSN, RN, CIC Director of Infection Prevention Highlights for the Medical Staff Pamela Rohrbach MSN, RN, CIC Director of Infection Prevention Standard Precautions every patient every time a. Hand Hygiene b. Use of Personal Protective Equipment (PPE)

More information

Help with moving disc diffusion methods from BSAC to EUCAST. Media BSAC EUCAST

Help with moving disc diffusion methods from BSAC to EUCAST. Media BSAC EUCAST Help with moving disc diffusion methods from BSAC to EUCAST This document sets out the main differences between the BSAC and EUCAST disc diffusion methods with specific emphasis on preparation prior to

More information

MICRONAUT MICRONAUT-S Detection of Resistance Mechanisms. Innovation with Integrity BMD MIC

MICRONAUT MICRONAUT-S Detection of Resistance Mechanisms. Innovation with Integrity BMD MIC MICRONAUT Detection of Resistance Mechanisms Innovation with Integrity BMD MIC Automated and Customized Susceptibility Testing For detection of resistance mechanisms and specific resistances of clinical

More information

EUCAST Subcommitee for Detection of Resistance Mechanisms (ESDReM)

EUCAST Subcommitee for Detection of Resistance Mechanisms (ESDReM) EUCAST Subcommitee for Detection of Resistance Mechanisms (ESDReM) Christian G. Giske, MD/PhD Chairman of ESDReM Karolinska University Hospital and EUCAST ECCMID, 22 maj 2013 The background Guidance on

More information

Taking Action to Prevent and Manage Multidrug-resistant Organisms and C. difficile in the Nursing Home: Part 1 Reviewing the organisms

Taking Action to Prevent and Manage Multidrug-resistant Organisms and C. difficile in the Nursing Home: Part 1 Reviewing the organisms Taking Action to Prevent and Manage Multidrug-resistant Organisms and C. difficile in the Nursing Home: Part 1 Reviewing the organisms Nimalie D. Stone, MD,MS Division of Healthcare Quality Promotion National

More information

Multi-Drug Resistant Gram Negative Organisms POLICY REVIEW DATE EXTENDED Printed copies must not be considered the definitive version

Multi-Drug Resistant Gram Negative Organisms POLICY REVIEW DATE EXTENDED Printed copies must not be considered the definitive version Multi-Drug Resistant Gram Negative Organisms POLICY REVIEW DATE EXTENDED 2018 Printed copies must not be considered the definitive version DOCUMENT CONTROL POLICY NO. IC-122 Policy Group Infection Control

More information

Understanding the Hospital Antibiogram

Understanding the Hospital Antibiogram Understanding the Hospital Antibiogram Sharon Erdman, PharmD Clinical Professor Purdue University College of Pharmacy Infectious Diseases Clinical Pharmacist Eskenazi Health 5 Understanding the Hospital

More information

Prevalence of Metallo-Beta-Lactamase Producing Pseudomonas aeruginosa and its antibiogram in a tertiary care centre

Prevalence of Metallo-Beta-Lactamase Producing Pseudomonas aeruginosa and its antibiogram in a tertiary care centre International Journal of Current Microbiology and Applied Sciences ISSN: 2319-7706 Volume 4 Number 9 (2015) pp. 952-956 http://www.ijcmas.com Original Research Article Prevalence of Metallo-Beta-Lactamase

More information

Antimicrobial Stewardship Strategy: Antibiograms

Antimicrobial Stewardship Strategy: Antibiograms Antimicrobial Stewardship Strategy: Antibiograms A summary of the cumulative susceptibility of bacterial isolates to formulary antibiotics in a given institution or region. Its main functions are to guide

More information

Imagine. Multi-Drug Resistant Superbugs- What s the Big Deal? A World. Without Antibiotics. Where Simple Infections can be Life Threatening

Imagine. Multi-Drug Resistant Superbugs- What s the Big Deal? A World. Without Antibiotics. Where Simple Infections can be Life Threatening Multi-Drug Resistant Superbugs- What s the Big Deal? Toni Biasi, RN MSN MPH CIC Infection Prevention Indiana University Health Imagine A World Without Antibiotics A World Where Simple Infections can be

More information

DR. BASHIRU BOI KIKIMOTO

DR. BASHIRU BOI KIKIMOTO OVERVIEW OF ANTIMICROBIAL RESISTANCE AND ANTIMICROBIAL USE IN GHANA PRESENTED BY : DR. BASHIRU BOI KIKIMOTO DVM. PhD VETERINARY PUBLIC HEALTH HEAD - PUBLIC HEALTH UNIT & FOOD SAFETY UNIT VENUE: SWATZILAND

More information

Suggestions for appropriate agents to include in routine antimicrobial susceptibility testing

Suggestions for appropriate agents to include in routine antimicrobial susceptibility testing Suggestions for appropriate agents to include in routine antimicrobial susceptibility testing These suggestions are intended to indicate minimum sets of agents to test routinely in a diagnostic laboratory

More information

National Surveillance of Antimicrobial Resistance

National Surveillance of Antimicrobial Resistance National Surveillance of Antimicrobial Resistance Report to Ministry of Health by Sri Lanka College of Microbiologists SLCM ARSP & NLBSA Technical Committees December 2014 National Surveillance of Antimicrobial

More information

GUIDE TO INFECTION CONTROL IN THE HOSPITAL. Antibiotic Resistance

GUIDE TO INFECTION CONTROL IN THE HOSPITAL. Antibiotic Resistance GUIDE TO INFECTION CONTROL IN THE HOSPITAL CHAPTER 4: Antibiotic Resistance Author M.P. Stevens, MD, MPH S. Mehtar, MD R.P. Wenzel, MD, MSc Chapter Editor Michelle Doll, MD, MPH Topic Outline Key Issues

More information

BSAC antimicrobial susceptibility

BSAC antimicrobial susceptibility BSAC antimicrobial susceptibility testing - from Stokes to European harmonization to world? Derek Brown 23 March 2011 BSAC antimicrobial susceptibility testing ti pre-working Party BSAC meetings from the

More information

Preventing Multi-Drug Resistant Organism (MDRO) Infections. For National Patient Safety Goal

Preventing Multi-Drug Resistant Organism (MDRO) Infections. For National Patient Safety Goal Preventing Multi-Drug Resistant Organism (MDRO) Infections For National Patient Safety Goal 07.03.01 2009 Methicillin Resistant Staphlococcus aureus (MRSA) About 3-8% of the population at large is a carrier

More information

Study of drug resistance pattern of principal ESBL producing urinary isolates in an urban hospital setting in Eastern India

Study of drug resistance pattern of principal ESBL producing urinary isolates in an urban hospital setting in Eastern India Research article Study of drug resistance pattern of principal ESBL producing urinary isolates in an urban hospital setting in Eastern India Mitali Chatterjee, 1 M. Banerjee, 1 S. Guha, 2 A.Lahiri, 3 K.Karak

More information

Other Enterobacteriaceae

Other Enterobacteriaceae GUIDE TO INFECTION CONTROL IN THE HOSPITAL CHAPTER NUMBER 50: Other Enterobacteriaceae Author Kalisvar Marimuthu, MD Chapter Editor Michelle Doll, MD, MPH Topic Outline Topic outline - Key Issues Known

More information

Int.J.Curr.Microbiol.App.Sci (2017) 6(3):

Int.J.Curr.Microbiol.App.Sci (2017) 6(3): International Journal of Current Microbiology and Applied Sciences ISSN: 2319-7706 Volume 6 Number 3 (2017) pp. 891-895 Journal homepage: http://www.ijcmas.com Original Research Article https://doi.org/10.20546/ijcmas.2017.603.104

More information

INCIDENCE OF BACTERIAL COLONISATION IN HOSPITALISED PATIENTS WITH DRUG-RESISTANT TUBERCULOSIS

INCIDENCE OF BACTERIAL COLONISATION IN HOSPITALISED PATIENTS WITH DRUG-RESISTANT TUBERCULOSIS INCIDENCE OF BACTERIAL COLONISATION IN HOSPITALISED PATIENTS WITH DRUG-RESISTANT TUBERCULOSIS 1 Research Associate, Drug Utilisation Research Unit, Nelson Mandela University 2 Human Sciences Research Council,

More information

Antimicrobial Resistance Strains

Antimicrobial Resistance Strains Antimicrobial Resistance Strains Microbiologics offers a wide range of strains with characterized antimicrobial resistance mechanisms including: Extended-Spectrum β-lactamases (ESBLs) Carbapenamases Vancomycin-Resistant

More information

European Committee on Antimicrobial Susceptibility Testing

European Committee on Antimicrobial Susceptibility Testing European Committee on Antimicrobial Susceptibility Testing Routine and extended internal quality control as recommended by EUCAST Version 5.0, valid from 015-01-09 This document should be cited as "The

More information

Intrinsic, implied and default resistance

Intrinsic, implied and default resistance Appendix A Intrinsic, implied and default resistance Magiorakos et al. [1] and CLSI [2] are our primary sources of information on intrinsic resistance. Sanford et al. [3] and Gilbert et al. [4] have been

More information

Hospital ID: 831. Bourguiba Hospital. Tertiary hospital

Hospital ID: 831. Bourguiba Hospital. Tertiary hospital Global Point Prevalence Survey of Antimicrobial Consumption and Resistance in hospitals worldwide Hospital ID: 831 Habib Bourguiba Hospital Tertiary hospital Tunisia Point Prevalence Survey Habib 2017

More information

ESCMID Online Lecture Library. by author

ESCMID Online Lecture Library. by author Quality Assurance of antimicrobial susceptibility testing Derek Brown EUCAST Scientific Secretary ESCMID Postgraduate Education Course, Linz, 17 September 2014 Quality Assurance The total process by which

More information

PROTOCOL for serotyping and antimicrobial susceptibility testing of Salmonella test strains

PROTOCOL for serotyping and antimicrobial susceptibility testing of Salmonella test strains PROTOCOL for serotyping and antimicrobial susceptibility testing of Salmonella test strains 1 INTRODUCTION... 1 2 OBJECTIVES... 2 3 OUTLINE OF THE EQAS 2017... 2 3.1 Shipping, receipt and storage of strains...

More information

5/4/2018. Multidrug Resistant Organisms (MDROs) Objectives. Outline. Define a multi-drug resistant organism (MDRO)

5/4/2018. Multidrug Resistant Organisms (MDROs) Objectives. Outline. Define a multi-drug resistant organism (MDRO) Multidrug Resistant Organisms (MDROs) Kasturi Shrestha, M.D. 05/11/2018 Objectives Define a multi-drug resistant organism (MDRO) Identify most challenging MDROs in healthcare Identify reasons for health

More information

How is Ireland performing on antibiotic prescribing?

How is Ireland performing on antibiotic prescribing? European Antibiotic Awareness Campaign 2016 November Webinar Series on Antibiotic Prescribing How is Ireland performing on antibiotic prescribing? Dr Rob Cunney National Clinical Lead HCAI AMR Clinical

More information

Mike Apley Kansas State University

Mike Apley Kansas State University Mike Apley Kansas State University 2003 - Daptomycin cyclic lipopeptides 2000 - Linezolid - oxazolidinones 1985 Imipenem - carbapenems 1978 - Norfloxacin - fluoroquinolones 1970 Cephalexin - cephalosporins

More information

The UK 5-year AMR Strategy - a brief overview - Dr Berit Muller-Pebody National Infection Service Public Health England

The UK 5-year AMR Strategy - a brief overview - Dr Berit Muller-Pebody National Infection Service Public Health England The UK 5-year AMR Strategy - a brief overview - Dr Berit Muller-Pebody National Infection Service Public Health England Chief Medical Officer - Annual Report 2013 Antimicrobial resistance poses catastrophic

More information

Multi-Drug Resistant Organisms (MDRO)

Multi-Drug Resistant Organisms (MDRO) Multi-Drug Resistant Organisms (MDRO) 2016 What are MDROs? Multi-drug resistant organisms, or MDROs, are bacteria resistant to current antibiotic therapy and therefore difficult to treat. MDROs can cause

More information

1/30/ Division of Disease Control and Health Protection. Division of Disease Control and Health Protection

1/30/ Division of Disease Control and Health Protection. Division of Disease Control and Health Protection Surveillance, Outbreaks, and Reportable Diseases, Oh My! Assisted Living Facility, Nursing Home and Surveyor Infection Prevention Training February 2015 A.C. Burke, MA, CIC Health Care-Associated Infection

More information

EDUCATIONAL COMMENTARY - Methicillin-Resistant Staphylococcus aureus: An Update

EDUCATIONAL COMMENTARY - Methicillin-Resistant Staphylococcus aureus: An Update EDUCATIONAL COMMENTARY - Methicillin-Resistant Staphylococcus aureus: An Update Educational commentary is provided through our affiliation with the American Society for Clinical Pathology (ASCP). To obtain

More information

Antibiotics in the future tense: The Application of Antibiotic Stewardship in Veterinary Medicine. Mike Apley Kansas State University

Antibiotics in the future tense: The Application of Antibiotic Stewardship in Veterinary Medicine. Mike Apley Kansas State University Antibiotics in the future tense: The Application of Antibiotic Stewardship in Veterinary Medicine Mike Apley Kansas State University Changes in Food Animal Antibiotic Use How the uses of antibiotics in

More information

Multidrug-Resistant Organisms: How Do We Define them? How do We Stop Them?

Multidrug-Resistant Organisms: How Do We Define them? How do We Stop Them? Multidrug-Resistant Organisms: How Do We Define them? How do We Stop Them? Roberta B. Carey, PhD Centers for Disease Control and Prevention Division of Healthcare Quality Promotion Why worry? MDROs Clinical

More information

Prevalence of Extended Spectrum Beta- Lactamase Producers among Various Clinical Samples in a Tertiary Care Hospital: Kurnool District, India

Prevalence of Extended Spectrum Beta- Lactamase Producers among Various Clinical Samples in a Tertiary Care Hospital: Kurnool District, India International Journal of Current Microbiology and Applied Sciences ISSN: 319-77 Volume Number (17) pp. 57-3 Journal homepage: http://www.ijcmas.com Original Research Article https://doi.org/1.5/ijcmas.17..31

More information

Antimicrobial Susceptibility Patterns

Antimicrobial Susceptibility Patterns Antimicrobial Susceptibility Patterns KNH SURGERY Department Masika M.M. Department of Medical Microbiology, UoN Medicines & Therapeutics Committee, KNH Outline Methodology Overall KNH data Surgery department

More information

9/30/2016. Dr. Janell Mayer, Pharm.D., CGP, BCPS Dr. Lindsey Votaw, Pharm.D., CGP, BCPS

9/30/2016. Dr. Janell Mayer, Pharm.D., CGP, BCPS Dr. Lindsey Votaw, Pharm.D., CGP, BCPS Dr. Janell Mayer, Pharm.D., CGP, BCPS Dr. Lindsey Votaw, Pharm.D., CGP, BCPS 1 2 Untoward Effects of Antibiotics Antibiotic resistance Adverse drug events (ADEs) Hypersensitivity/allergy Drug side effects

More information

Antimicrobial Susceptibility Testing: Advanced Course

Antimicrobial Susceptibility Testing: Advanced Course Antimicrobial Susceptibility Testing: Advanced Course Cascade Reporting Cascade Reporting I. Selecting Antimicrobial Agents for Testing and Reporting Selection of the most appropriate antimicrobials to

More information

2016 Antibiotic Susceptibility Report

2016 Antibiotic Susceptibility Report Fairview Northland Medical Center and Elk River, Milaca, Princeton and Zimmerman Clinics 2016 Antibiotic Susceptibility Report GRAM-NEGATIVE ORGANISMS 2016 Gram-Negative Non-Urine The number of isolates

More information

Implementing Antibiotic Stewardship in Rural and Critical Access Hospitals

Implementing Antibiotic Stewardship in Rural and Critical Access Hospitals National Center for Emerging and Zoonotic Infectious Diseases Implementing Antibiotic Stewardship in Rural and Critical Access Hospitals Denise Cardo, MD Director, Division of Healthcare Quality Promotion,

More information

Educating Clinical and Public Health Laboratories About Antimicrobial Resistance Challenges

Educating Clinical and Public Health Laboratories About Antimicrobial Resistance Challenges Educating Clinical and Public Health Laboratories About Antimicrobial Resistance Challenges Janet Hindler, MCLS MT(ASCP) UCLA Medical Center jhindler@ucla.edu also working as a consultant with the Association

More information

Antibacterial therapy 1. د. حامد الزعبي Dr Hamed Al-Zoubi

Antibacterial therapy 1. د. حامد الزعبي Dr Hamed Al-Zoubi Antibacterial therapy 1 د. حامد الزعبي Dr Hamed Al-Zoubi ILOs Principles and terms Different categories of antibiotics Spectrum of activity and mechanism of action Resistancs Antibacterial therapy What

More information

Antimicrobial Susceptibility Testing: The Basics

Antimicrobial Susceptibility Testing: The Basics Antimicrobial Susceptibility Testing: The Basics Susan E. Sharp, Ph.D., DABMM, FAAM Director, Airport Way Regional Laboratory Director, Regional Microbiology and Molecular Infectious Diseases Laboratories

More information

جداول میکروارگانیسم های بیماریزای اولویت دار و آنتی بیوتیک های تعیین شده برای آزمایش تعیین حساسیت ضد میکروبی در برنامه مهار مقاومت میکروبی

جداول میکروارگانیسم های بیماریزای اولویت دار و آنتی بیوتیک های تعیین شده برای آزمایش تعیین حساسیت ضد میکروبی در برنامه مهار مقاومت میکروبی جداول میکروارگانیسم های بیماریزای اولویت دار و آنتی بیوتیک های تعیین شده برای آزمایش تعیین حساسیت ضد میکروبی در برنامه مهار مقاومت میکروبی ویرایش دوم بر اساس ed., 2017 CLSI M100 27 th تابستان ۶۹۳۱ تهیه

More information

Infection Control of Emerging Diseases

Infection Control of Emerging Diseases 2016 EPS Training Event Martin E. Evans, MD Director, VHA MDRO Program National Infectious Diseases Service Lexington, KY & Cincinnati, OH Infection Control of Emerging Diseases 2016 EPS Training Event

More information

CLSI vs. EUCAST. What is EUCAST? Structure of EUCAST CLSI. Where they fit? SASCM WORKSHOP 5/24/2014

CLSI vs. EUCAST. What is EUCAST? Structure of EUCAST CLSI. Where they fit? SASCM WORKSHOP 5/24/2014 vs. Olga Perovic, Principal Pathologist, Center for Opportunistic, Tropical and Hospital Infections, Associate Professor at WITS, Saturday, May 24, 2014 A not-for-profit membership organization, the Clinical

More information

THE NAC CHALLENGE PANEL OF ISOLATES FOR VERIFICATION OF ANTIBIOTIC SUSCEPTIBILITY TESTING METHODS

THE NAC CHALLENGE PANEL OF ISOLATES FOR VERIFICATION OF ANTIBIOTIC SUSCEPTIBILITY TESTING METHODS THE NAC CHALLENGE PANEL OF ISOLATES FOR VERIFICATION OF ANTIBIOTIC SUSCEPTIBILITY TESTING METHODS Stefanie Desmet University Hospitals Leuven Laboratory medicine microbiology stefanie.desmet@uzleuven.be

More information

Antibiotic. Antibiotic Classes, Spectrum of Activity & Antibiotic Reporting

Antibiotic. Antibiotic Classes, Spectrum of Activity & Antibiotic Reporting Antibiotic Antibiotic Classes, Spectrum of Activity & Antibiotic Reporting Any substance of natural, synthetic or semisynthetic origin which at low concentrations kills or inhibits the growth of bacteria

More information

A retrospective analysis of urine culture results issued by the microbiology department, Teaching Hospital, Karapitiya

A retrospective analysis of urine culture results issued by the microbiology department, Teaching Hospital, Karapitiya A retrospective analysis of urine culture results issued by the microbiology department, Teaching Hospital, Karapitiya LU Edirisinghe 1, D Vidanagama 2 1 Senior Registrar in Medicine, 2 Consultant Microbiologist,

More information

Multi-drug resistant microorganisms

Multi-drug resistant microorganisms Multi-drug resistant microorganisms Arzu TOPELI Director of MICU Hacettepe University Faculty of Medicine, Ankara-Turkey Council Member of WFSICCM Deaths in the US declined by 220 per 100,000 with the

More information

Concise Antibiogram Toolkit Background

Concise Antibiogram Toolkit Background Background This toolkit is designed to guide nursing homes in creating their own antibiograms, an important tool for guiding empiric antimicrobial therapy. Information about antibiograms and instructions

More information

Public Health Response to Emerging Resistance

Public Health Response to Emerging Resistance National Center for Emerging and Zoonotic Infectious Diseases Public Health Response to Emerging Resistance Alex Kallen, MD, MPH, FACP Lead Antimicrobial Resistance and Emerging Pathogens Team Prevention

More information

Background and Plan of Analysis

Background and Plan of Analysis ENTEROCOCCI Background and Plan of Analysis UR-11 (2017) was sent to API participants as a simulated urine culture for recognition of a significant pathogen colony count, to perform the identification

More information

Carbapenemase-Producing Enterobacteriaceae (CPE)

Carbapenemase-Producing Enterobacteriaceae (CPE) Carbapenemase-Producing Enterobacteriaceae (CPE) September 21, 2017 Maryam Khan Peel Public Health Madeleine Ashcroft Public Health Ontario Objectives Differentiate the acronyms related to CPE (CPE,CPO,CRE,CRO)

More information

Other Beta - lactam Antibiotics

Other Beta - lactam Antibiotics Other Beta - lactam Antibiotics Assistant Professor Dr. Naza M. Ali Lec 5 8 Nov 2017 Lecture outlines Other beta lactam antibiotics Other inhibitors of cell wall synthesis Other beta-lactam Antibiotics

More information

Defining Extended Spectrum b-lactamases: Implications of Minimum Inhibitory Concentration- Based Screening Versus Clavulanate Confirmation Testing

Defining Extended Spectrum b-lactamases: Implications of Minimum Inhibitory Concentration- Based Screening Versus Clavulanate Confirmation Testing Infect Dis Ther (2015) 4:513 518 DOI 10.1007/s40121-015-0094-6 BRIEF REPORT Defining Extended Spectrum b-lactamases: Implications of Minimum Inhibitory Concentration- Based Screening Versus Clavulanate

More information

Microbiology. Multi-Drug-Resistant bacteria / MDR: laboratory diagnostics and prevention. Antimicrobial resistance / MDR:

Microbiology. Multi-Drug-Resistant bacteria / MDR: laboratory diagnostics and prevention. Antimicrobial resistance / MDR: Microbiology Multi-Drug-Resistant bacteria / MDR: laboratory diagnostics and prevention June 2017 MeshHp (VS) Medical Care Center Dr. Eberhard & Partner Dortmund (ÜBAG) www.labmed.de MVZ Dr. Eberhard &

More information

Overview of Infection Control and Prevention

Overview of Infection Control and Prevention Overview of Infection Control and Prevention Review of the Cesarean-section Antibiotic Prophylaxis Program in Jordan and Workshop on Rational Medicine Use and Infection Control Terry Green and Salah Gammouh

More information

CONTAGIOUS COMMENTS Department of Epidemiology

CONTAGIOUS COMMENTS Department of Epidemiology VOLUME XXIII NUMBER 1 July 2008 CONTAGIOUS COMMENTS Department of Epidemiology Bugs and Drugs Elaine Dowell, SM (ASCP), Marti Roe SM (ASCP), Ann-Christine Nyquist MD, MSPH Are the bugs winning? The 2007

More information

Stratégie et action européennes

Stratégie et action européennes Résistance aux antibiotiques : une impasse thérapeutique? Implications nationales et internationales Stratégie et action européennes Dominique L. Monnet, Senior Expert and Head of Disease Programme Antimicrobial

More information

Recommendations for Implementation of Antimicrobial Stewardship Restrictive Interventions in Acute Hospitals in Ireland

Recommendations for Implementation of Antimicrobial Stewardship Restrictive Interventions in Acute Hospitals in Ireland Recommendations for Implementation of Antimicrobial Stewardship Restrictive Interventions in Acute Hospitals in Ireland A report by the Hospital Antimicrobial Stewardship Working Group, a subgroup of the

More information

Regional Workshop on AMR in South East Asia Penang (Malaysia): March 2018

Regional Workshop on AMR in South East Asia Penang (Malaysia): March 2018 Regional Workshop on AMR in South East Asia Penang (Malaysia): 26-28 March 2018 Prof : Htay Htay Tin drhtayhtaytin@gmail.com DDG ( Laboratory) National Focal Point for AMR Ministry of Health and Sports

More information

Helen Heffernan and Rosemary Woodhouse Antibiotic Reference Laboratory

Helen Heffernan and Rosemary Woodhouse Antibiotic Reference Laboratory METHODS USED IN NEW ZEALAND DIAGNOSTIC LABORATORIES TO IDENTIFY AND REPORT EXTENDED-SPECTRUM β-lactamase- PRODUCING ENTEROBACTERIACEAE by Helen Heffernan and Rosemary Woodhouse Antibiotic Reference Laboratory

More information

Antimicrobial Cycling. Donald E Low University of Toronto

Antimicrobial Cycling. Donald E Low University of Toronto Antimicrobial Cycling Donald E Low University of Toronto Bad Bugs, No Drugs 1 The Antimicrobial Availability Task Force of the IDSA 1 identified as particularly problematic pathogens A. baumannii and

More information

COMMISSION OF THE EUROPEAN COMMUNITIES

COMMISSION OF THE EUROPEAN COMMUNITIES COMMISSION OF THE EUROPEAN COMMUNITIES Brussels, 22 December 2005 COM (2005) 0684 REPORT FROM THE COMMISSION TO THE COUNCIL ON THE BASIS OF MEMBER STATES REPORTS ON THE IMPLEMENTATION OF THE COUNCIL RECOMMENDATION

More information

Rise of Resistance: From MRSA to CRE

Rise of Resistance: From MRSA to CRE Rise of Resistance: From MRSA to CRE Paul D. Holtom, MD Professor of Medicine and Orthopaedics USC Keck School of Medicine SUPERBUGS (AKA MDROs) MRSA Methicillin-resistant S. aureus Evolution of Drug Resistance

More information

What s new in EUCAST methods?

What s new in EUCAST methods? What s new in EUCAST methods? Derek Brown EUCAST Scientific Secretary Interactive question 1 MIC determination MH-F broth for broth microdilution testing of fastidious microorganisms Gradient MIC tests

More information

Quality assurance of antimicrobial susceptibility testing

Quality assurance of antimicrobial susceptibility testing Quality assurance of antimicrobial susceptibility testing Derek Brown Routine quality control Repeated testing of controls in parallel with tests to ensure that the test system is performing reproducibly

More information

The Basics: Using CLSI Antimicrobial Susceptibility Testing Standards

The Basics: Using CLSI Antimicrobial Susceptibility Testing Standards The Basics: Using CLSI Antimicrobial Susceptibility Testing Standards Janet A. Hindler, MCLS, MT(ASCP) UCLA Health System Los Angeles, California, USA jhindler@ucla.edu 1 Learning Objectives Describe information

More information

3/1/2016. Antibiotics --When Less is More. Most Urgent Threats. Serious Threats

3/1/2016. Antibiotics --When Less is More. Most Urgent Threats. Serious Threats Antibiotics --When Less is More Ralph Gonzales, MD, MSPH Associate Dean, Clinical Innovation School of Medicine VP, Clinical Innovation, UCSF Health Most Urgent Threats Serious Threats Multidrug-Resistant

More information

Antibiotics: mode of action and mechanisms of resistance. Slides made by Special consultant Henrik Hasman Statens Serum Institut

Antibiotics: mode of action and mechanisms of resistance. Slides made by Special consultant Henrik Hasman Statens Serum Institut Antibiotics: mode of action and mechanisms of resistance. Slides made by Special consultant Henrik Hasman Statens Serum Institut This presentation Definitions needed to discuss antimicrobial resistance

More information

Healthcare Facilities and Healthcare Professionals. Public

Healthcare Facilities and Healthcare Professionals. Public Document Title: DOH Guidelines for Antimicrobial Stewardship Programs Document Ref. Number: DOH/ASP/GL/1.0 Version: 1.0 Approval Date: 13/12/2017 Effective Date: 14/12/2017 Document Owner: Applies to:

More information

PRACTIC GUIDELINES for APPROPRIATE ANTIBIOTICS USE

PRACTIC GUIDELINES for APPROPRIATE ANTIBIOTICS USE PRACTIC GUIDELINES for APPROPRIATE ANTIBIOTICS USE Global Alliance for Infection in Surgery World Society of Emergency Surgery (WSES) and not only!! Aims - 1 Rationalize the risk of antibiotics overuse

More information

January 2014 Vol. 34 No. 1

January 2014 Vol. 34 No. 1 January 2014 Vol. 34 No. 1. and Minimum Inhibitory Concentration (MIC) Interpretive Standards for Testing Conditions Medium: diffusion: Mueller-Hinton agar (MHA) Broth dilution: cation-adjusted Mueller-Hinton

More information

ALARMING RATES OF PREVALENCE OF ESBL PRODUCING E. COLI IN URINARY TRACT INFECTION CASES IN A TERTIARY CARE NEUROSPECIALITY HOSPITAL

ALARMING RATES OF PREVALENCE OF ESBL PRODUCING E. COLI IN URINARY TRACT INFECTION CASES IN A TERTIARY CARE NEUROSPECIALITY HOSPITAL ALARMING RATES OF PREVALENCE OF ESBL PRODUCING E. COLI IN URINARY TRACT INFECTION CASES IN A TERTIARY CARE NEUROSPECIALITY HOSPITAL Pearl. A Prabal*,Sourav Maiti Institute of Neurosciences, Kolkata, India

More information

Surveillance of AMR in PHE: a multidisciplinary,

Surveillance of AMR in PHE: a multidisciplinary, Surveillance of AMR in PHE: a multidisciplinary, integrated approach Professor Neil Woodford Antimicrobial Resistance & Healthcare Associated Infections (AMRHAI) Reference Unit Crown copyright International

More information

WHO s first global report on antibiotic resistance reveals serious, worldwide threat to public health

WHO s first global report on antibiotic resistance reveals serious, worldwide threat to public health New WHO report provides the most comprehensive picture of antibiotic resistance to date, with data from 114 countries 30 APRIL 2014 GENEVA - A new report by WHO its first to look at antimicrobial resistance,

More information

What s next in the antibiotic pipeline?

What s next in the antibiotic pipeline? What s next in the antibiotic pipeline? Jennifer Tieu, Pharm.D., BCPS Clinical Pearls OSHP Spring Meeting Mercy Hospital April 13, 2018 Objective 2 Describe the drug class and mechanism of action of antibiotics

More information

New Drugs for Bad Bugs- Statewide Antibiogram

New Drugs for Bad Bugs- Statewide Antibiogram New Drugs for Bad Bugs- Statewide Antibiogram Felicia Matthews, Pharm.D., BCPS Senior Consultant, Pharmacy Specialty BE MedMined Services Disclosures Employee of BD Corporation MedMined Services Agenda

More information

Antibiotic Resistance. Antibiotic Resistance: A Growing Concern. Antibiotic resistance is not new 3/21/2011

Antibiotic Resistance. Antibiotic Resistance: A Growing Concern. Antibiotic resistance is not new 3/21/2011 Antibiotic Resistance Antibiotic Resistance: A Growing Concern Judy Ptak RN MSN Infection Prevention Practitioner Dartmouth-Hitchcock Medical Center Lebanon, NH Occurs when a microorganism fails to respond

More information

Detection of ESBL Producing Gram Negative Uropathogens and their Antibiotic Resistance Pattern from a Tertiary Care Centre, Bengaluru, India

Detection of ESBL Producing Gram Negative Uropathogens and their Antibiotic Resistance Pattern from a Tertiary Care Centre, Bengaluru, India ISSN: 2319-7706 Volume 4 Number 12 (2015) pp. 578-583 http://www.ijcmas.com Original Research Article Detection of ESBL Producing Gram Negative Uropathogens and their Antibiotic Resistance Pattern from

More information

2015 Antibiotic Susceptibility Report

2015 Antibiotic Susceptibility Report Citrobacter freundii Enterobacter aerogenes Enterobacter cloacae Escherichia coli Haemophilus influenzenza Klebsiella oxytoca Klebsiella pneumoniae Proteus mirabilis Pseudomonas aeruginosa Serratia marcescens

More information

Volume-7, Issue-2, April-June-2016 Coden IJABFP-CAS-USA Received: 5 th Mar 2016 Revised: 11 th April 2016 Accepted: 13 th April 2016 Research article

Volume-7, Issue-2, April-June-2016 Coden IJABFP-CAS-USA Received: 5 th Mar 2016 Revised: 11 th April 2016 Accepted: 13 th April 2016 Research article Volume-7, Issue-2, April-June-2016 Coden IJABFP-CAS-USA Copyrights@2016 Received: 5 th Mar 2016 Revised: 11 th April 2016 Accepted: 13 th April 2016 Research article A STUDY ON ANTIBIOTIC SUSCEPTIBILITY

More information

GENERAL NOTES: 2016 site of infection type of organism location of the patient

GENERAL NOTES: 2016 site of infection type of organism location of the patient GENERAL NOTES: This is a summary of the antibiotic sensitivity profile of clinical isolates recovered at AIIMS Bhopal Hospital during the year 2016. However, for organisms in which < 30 isolates were recovered

More information